<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Jpn J Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Jpn. J. Cancer Res</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006a</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Japanese Journal of Cancer Research : Gann</journal-title></journal-title-group><issn pub-type="ppub">0910-5050</issn><issn pub-type="epub">1876-4673</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">12359061</article-id><article-id pub-id-type="pmc">5927129</article-id><article-id pub-id-type="doi">10.1111/j.1349-7006.2002.tb02484.x</article-id><article-id pub-id-type="publisher-id">CAE1063</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Dose&#x02010;response Trial of Lactoferrin in Patients with Chronic Hepatitis C</article-title></title-group><contrib-group><contrib id="cr1" contrib-type="author" corresp="yes"><name><surname>Okada</surname><given-names>Shuichi</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr2" contrib-type="author"><name><surname>Tanaka</surname><given-names>Katsuaki</given-names></name><xref ref-type="aff" rid="a5"><sup>5</sup></xref></contrib><contrib id="cr3" contrib-type="author"><name><surname>Sato</surname><given-names>Tosiya</given-names></name><xref ref-type="aff" rid="a6"><sup>6</sup></xref></contrib><contrib id="cr4" contrib-type="author"><name><surname>Ueno</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr5" contrib-type="author"><name><surname>Saito</surname><given-names>Satoru</given-names></name><xref ref-type="aff" rid="a5"><sup>5</sup></xref></contrib><contrib id="cr6" contrib-type="author"><name><surname>Okusaka</surname><given-names>Takuji</given-names></name><xref ref-type="aff" rid="a1"><sup>1</sup></xref></contrib><contrib id="cr7" contrib-type="author"><name><surname>Sato</surname><given-names>Keiko</given-names></name><xref ref-type="aff" rid="a2"><sup>2</sup></xref></contrib><contrib id="cr8" contrib-type="author"><name><surname>Yamamoto</surname><given-names>Seiichiro</given-names></name><xref ref-type="aff" rid="a3"><sup>3</sup></xref></contrib><contrib id="cr9" contrib-type="author"><name><surname>Kakizoe</surname><given-names>Tadao</given-names></name><xref ref-type="aff" rid="a4"><sup>4</sup></xref></contrib></contrib-group><aff id="a1"><label><sup>1</sup></label>Hepatobiliary and Pancreatic Oncology Division, 5&#x02010;1&#x02010;1 Tsukiji, Chuo&#x02010;ku, Tokyo 104&#x02010;0045</aff><aff id="a2"><label><sup>2</sup></label>Clinical Research Coordinating Office, National Cancer Center Hospital, 5&#x02010;1&#x02010;1 Tsukiji, Chuo&#x02010;ku, Tokyo 104&#x02010;0045</aff><aff id="a3"><label><sup>3</sup></label>Cancer Information and Epidemiology Division, National Cancer Center Research Institute, 5&#x02010;1&#x02010;1 Tsukiji, Chuo&#x02010;ku, Tokyo 104&#x02010;0045</aff><aff id="a4"><label><sup>4</sup></label>National Cancer Center, 5&#x02010;1&#x02010;1 Tsukiji, Chuo&#x02010;ku, Tokyo 104&#x02010;0045</aff><aff id="a5"><label><sup>5</sup></label>Gastroenterological Center, Yokohama City University Medical Center, 4&#x02010;5 Urafune&#x02010;cho, Minami&#x02010;ku, Yokohama 232&#x02010;0024</aff><aff id="a6"><label><sup>6</sup></label>Department of Epidemiology and Biostatistics, Kyoto University School of Public Health, Yoshidakonoe&#x02010;cho, Sakyo&#x02010;ku, Kyoto 606&#x02010;8501</aff><author-notes><corresp id="correspondenceTo"><label>*</label>E&#x02010;mail: <email>sokada@ncc.go.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2002</year></pub-date><volume>93</volume><issue>9</issue><issue-id pub-id-type="doi">10.1111/cas.2002.93.issue-9</issue-id><fpage>1063</fpage><lpage>1069</lpage><history>
(Received April 22, 2002/Revised June 10, 2002/Accepted June 19, 2002)</history><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-93-1063.pdf"/><abstract><p>Hepatitis C virus (HCV) is one of the most common causes of chronic hepatitis. Interferon is presently the only effective treatment for chronic hepatitis C (CH&#x02010;C), though its effectiveness is limited. Lactoferrin (LF), which is an 80&#x02010;kDa, iron&#x02010;binding glycoprotein, has several biological activities including anti&#x02010;viral activity, and it was recently reported to inhibit HCV infection in cultured human hepatocytes. The present trial was designed to assess the relationship between the dose of bovine LF (bLF) and the effect of bLF on serum alanine aminotransaminase (ALT) and HCV RNA levels in patients with CH&#x02010;C. Forty&#x02010;five patients entered at each of the three dose levels (bLF of 1.8, 3.6, and 7.2 g/day) received orally an 8&#x02010;week course of bLF. There was no significant relation between the dose of bLF and the effect of bLF on serum ALT or HCV RNA levels. Biochemical (a 50% or greater decrease in the serum ALT level) and virological (a 50% or greater decrease in HCV RNA level) responses were observed in two and four patients, respectively, but all responders relapsed during the follow&#x02010;up period after bLF treatment. The bLF treatment was generally well tolerated, and no patient had any serious adverse event. In conclusion, the excellent tolerance and potential anti&#x02010;HCV activity of bLF shown in this trial suggest that further trials using a large number of patients are mandatory. We are currently conducting a double&#x02010;blind randomized controlled trial comparing bLF with placebo to clarify the anti&#x02010;HCV activity of bLF in patients with CH&#x02010;C.</p></abstract><kwd-group><kwd id="k1">Lactoferrin</kwd><kwd id="k2">Chronic hepatitis C</kwd><kwd id="k3">Hepatitis C virus</kwd><kwd id="k4">Alanine aminotransaminase</kwd></kwd-group><counts><ref-count count="32"/><page-count count="7"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2002</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015</meta-value></custom-meta></custom-meta-group></article-meta></front><back><ref-list id="ss1"><title>REFERENCES</title><ref id="b1"><label>1</label><mixed-citation publication-type="journal" id="cit1">
)
<string-name><surname>Di Bisceglie</surname>
,
<given-names>A. M.</given-names></string-name><article-title>Hepatitis C and hepatocellular carcinoma</article-title>
.
<source>Hepatology</source>
,
<volume>26</volume>
(
<issue>Suppl. 1</issue>
),
<fpage>34S</fpage>
&#x02013;
<lpage>38S</lpage>
(
<year>1997</year>
).
<pub-id pub-id-type="pmid">9305661</pub-id></mixed-citation></ref><ref id="b2"><label>2</label><mixed-citation publication-type="journal" id="cit2">
)
<string-name><surname>Takano</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Yokosuka</surname>
,
<given-names>O.</given-names></string-name>
,
<string-name><surname>Imazeki</surname>
,
<given-names>F.</given-names></string-name>
,
<string-name><surname>Tagawa</surname>
,
<given-names>M.</given-names></string-name>
and
<string-name><surname>Omata</surname>
,
<given-names>M.</given-names></string-name><article-title>Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients</article-title>
.
<source>Hepatology</source>
,
<volume>21</volume>
,
<fpage>650</fpage>
&#x02013;
<lpage>655</lpage>
(
<year>1995</year>
).
<pub-id pub-id-type="pmid">7875662</pub-id></mixed-citation></ref><ref id="b3"><label>3</label><mixed-citation publication-type="journal" id="cit3">
)
<string-name><surname>Niederau</surname>
,
<given-names>C.</given-names></string-name>
,
<string-name><surname>Lange</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Heintges</surname>
,
<given-names>T.</given-names></string-name>
,
<string-name><surname>Erhardt</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Buschikamp</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Hurter</surname>
,
<given-names>D.</given-names></string-name>
,
<string-name><surname>Nawrocki</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Kruska</surname>
,
<given-names>L.</given-names></string-name>
,
<string-name><surname>Hensel</surname>
,
<given-names>F.</given-names></string-name>
,
<string-name><surname>Petty</surname>
,
<given-names>W.</given-names></string-name>
and
<string-name><surname>Haussingger</surname>
,
<given-names>D.</given-names></string-name><article-title>Prognosis of chronic hepatitis C: results of a large, prospective cohort study</article-title>
.
<source>Hepatology</source>
,
<volume>28</volume>
,
<fpage>1687</fpage>
&#x02013;
<lpage>1695</lpage>
(
<year>1998</year>
).
<pub-id pub-id-type="pmid">9828236</pub-id></mixed-citation></ref><ref id="b4"><label>4</label><mixed-citation publication-type="journal" id="cit4">
)
<string-name><surname>Hoofnagle</surname>
,
<given-names>J. H.</given-names></string-name>
and
<string-name><surname>Di Bisceglie</surname>
,
<given-names>A. M.</given-names></string-name><article-title>The treatment of chronic viral hepatitis</article-title>
.
<source>N. Engl. J. Med.</source>
,
<volume>336</volume>
,
<fpage>347</fpage>
&#x02013;
<lpage>356</lpage>
(
<year>1997</year>
).
<pub-id pub-id-type="pmid">9011789</pub-id></mixed-citation></ref><ref id="b5"><label>5</label><mixed-citation publication-type="journal" id="cit5">
)
<string-name><surname>Davis</surname>
,
<given-names>G. L.</given-names></string-name><article-title>Current therapy for chronic hepatitis C</article-title>
.
<source>Gastroenterology</source>
,
<volume>118</volume>
,
<fpage>S104</fpage>
&#x02013;
<lpage>S114</lpage>
(
<year>2000</year>
).
<pub-id pub-id-type="pmid">10868901</pub-id></mixed-citation></ref><ref id="b6"><label>6</label><mixed-citation publication-type="journal" id="cit6">
)
<string-name><surname>McHutchison</surname>
,
<given-names>J. G.</given-names></string-name>
,
<string-name><surname>Gordon</surname>
,
<given-names>S. C.</given-names></string-name>
,
<string-name><surname>Schiff</surname>
,
<given-names>E. R.</given-names></string-name>
,
<string-name><surname>Shiffman</surname>
,
<given-names>M. L.</given-names></string-name>
,
<string-name><surname>Lee</surname>
,
<given-names>W. M.</given-names></string-name>
,
<string-name><surname>Rustgi</surname>
,
<given-names>V. K.</given-names></string-name>
,
<string-name><surname>Goodman</surname>
,
<given-names>Z. D.</given-names></string-name>
,
<string-name><surname>Ling</surname>
,
<given-names>M. H.</given-names></string-name>
,
<string-name><surname>Cort</surname>
,
<given-names>S.</given-names></string-name>
and
<string-name><surname>Albrecht</surname>
,
<given-names>J. K.</given-names></string-name><article-title>Interferon alfa&#x02010;2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C</article-title>
.
<source>N. Engl. J. Med.</source>
,
<volume>339</volume>
,
<fpage>1485</fpage>
&#x02013;
<lpage>1492</lpage>
(
<year>1998</year>
).
<pub-id pub-id-type="pmid">9819446</pub-id></mixed-citation></ref><ref id="b7"><label>7</label><mixed-citation publication-type="journal" id="cit7">
)
<string-name><surname>Davis</surname>
,
<given-names>G. L.</given-names></string-name>
,
<string-name><surname>Esteban&#x02010;Mur</surname>
,
<given-names>R.</given-names></string-name>
,
<string-name><surname>Rustgi</surname>
,
<given-names>V.</given-names></string-name>
,
<string-name><surname>Hoefs</surname>
,
<given-names>J.</given-names></string-name>
,
<string-name><surname>Gordon</surname>
,
<given-names>S. C.</given-names></string-name>
,
<string-name><surname>Trepo</surname>
,
<given-names>C.</given-names></string-name>
,
<string-name><surname>Shiffman</surname>
,
<given-names>M. L.</given-names></string-name>
,
<string-name><surname>Zeuzem</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Craxi</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Ling</surname>
,
<given-names>M. H.</given-names></string-name>
and
<string-name><surname>Albrecht</surname>
,
<given-names>J.</given-names></string-name><article-title>Interferon alfa&#x02010;2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C</article-title>
.
<source>N. Engl. J. Med.</source>
,
<volume>339</volume>
,
<fpage>1493</fpage>
&#x02013;
<lpage>1499</lpage>
(
<year>1998</year>
).
<pub-id pub-id-type="pmid">9819447</pub-id></mixed-citation></ref><ref id="b8"><label>8</label><mixed-citation publication-type="journal" id="cit8">
)
<string-name><surname>Poynard</surname>
,
<given-names>T.</given-names></string-name>
,
<string-name><surname>Marcellin</surname>
,
<given-names>P.</given-names></string-name>
,
<string-name><surname>Lee</surname>
,
<given-names>S. S.</given-names></string-name>
,
<string-name><surname>Niederau</surname>
,
<given-names>C.</given-names></string-name>
,
<string-name><surname>Minuk</surname>
,
<given-names>G. S.</given-names></string-name>
,
<string-name><surname>Ideo</surname>
,
<given-names>G.</given-names></string-name>
,
<string-name><surname>Bain</surname>
,
<given-names>V.</given-names></string-name>
,
<string-name><surname>Heathcote</surname>
,
<given-names>J.</given-names></string-name>
,
<string-name><surname>Zeuzem</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Trepo</surname>
,
<given-names>C.</given-names></string-name>
and
<string-name><surname>Albrecht</surname>
,
<given-names>J.</given-names></string-name><article-title>Randomised trial of interferon &#x003b4;2b plus ribavirin for 48 weeks or for 24 weeks versus interferon &#x003b4;2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus</article-title>
.
<source>Lancet</source>
,
<volume>352</volume>
,
<fpage>1426</fpage>
&#x02013;
<lpage>1432</lpage>
(
<year>1998</year>
).
<pub-id pub-id-type="pmid">9807989</pub-id></mixed-citation></ref><ref id="b9"><label>9</label><mixed-citation publication-type="journal" id="cit9">
)
<string-name><surname>Zeuzem</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Feinman</surname>
,
<given-names>S. V.</given-names></string-name>
,
<string-name><surname>Rasenack</surname>
,
<given-names>J.</given-names></string-name>
,
<string-name><surname>Heathcote</surname>
,
<given-names>E. J.</given-names></string-name>
,
<string-name><surname>Lai</surname>
,
<given-names>M.&#x02010;Y.</given-names></string-name>
,
<string-name><surname>Gane</surname>
,
<given-names>E.</given-names></string-name>
,
<string-name><surname>O'Grady</surname>
,
<given-names>J.</given-names></string-name>
,
<string-name><surname>Reichen</surname>
,
<given-names>J.</given-names></string-name>
,
<string-name><surname>Diago</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Lin</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Hoffman</surname>
,
<given-names>J.</given-names></string-name>
and
<string-name><surname>Brunda</surname>
,
<given-names>M. J.</given-names></string-name><article-title>Peginterferon alfa&#x02010;2a in patients with chronic hepatitis C</article-title>
.
<source>N. Engl. J. Med.</source>
,
<volume>343</volume>
,
<fpage>1666</fpage>
&#x02013;
<lpage>1672</lpage>
(
<year>2000</year>
).
<pub-id pub-id-type="pmid">11106715</pub-id></mixed-citation></ref><ref id="b10"><label>10</label><mixed-citation publication-type="journal" id="cit10">
)
<string-name><surname>Heathcote</surname>
,
<given-names>E. J.</given-names></string-name>
,
<string-name><surname>Shiffman</surname>
,
<given-names>M. L.</given-names></string-name>
,
<string-name><surname>Cooksley</surname>
,
<given-names>G. E.</given-names></string-name>
,
<string-name><surname>Dusheiko</surname>
,
<given-names>G. M.</given-names></string-name>
,
<string-name><surname>Lee</surname>
,
<given-names>S. S.</given-names></string-name>
,
<string-name><surname>Balart</surname>
,
<given-names>L.</given-names></string-name>
,
<string-name><surname>Reindollar</surname>
,
<given-names>R.</given-names></string-name>
,
<string-name><surname>Reddy</surname>
,
<given-names>R. K.</given-names></string-name>
,
<string-name><surname>Wright</surname>
,
<given-names>T. L.</given-names></string-name>
,
<string-name><surname>Lin</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Hoffman</surname>
,
<given-names>J.</given-names></string-name>
and
<string-name><surname>De Pamphilis</surname>
,
<given-names>J.</given-names></string-name><article-title>Peginterferon alfa&#x02010;2a in patients with chronic hepatitis C and cirrhosis</article-title>
.
<source>N. Engl. J. Med.</source>
,
<volume>343</volume>
,
<fpage>1673</fpage>
&#x02013;
<lpage>1680</lpage>
(
<year>2000</year>
).
<pub-id pub-id-type="pmid">11106716</pub-id></mixed-citation></ref><ref id="b11"><label>11</label><mixed-citation publication-type="journal" id="cit11">
)
<string-name><surname>Lonnerdal</surname>
,
<given-names>B.</given-names></string-name>
and
<string-name><surname>Iyer</surname>
,
<given-names>S.</given-names></string-name><article-title>Lactoferrin: molecular structure and biological function</article-title>
.
<source>Annu. Rev. Nutr.</source>
,
<volume>15</volume>
,
<fpage>93</fpage>
&#x02013;
<lpage>110</lpage>
(
<year>1995</year>
).
<pub-id pub-id-type="pmid">8527233</pub-id></mixed-citation></ref><ref id="b12"><label>12</label><mixed-citation publication-type="journal" id="cit12">
)
<string-name><surname>Levay</surname>
,
<given-names>P. F.</given-names></string-name>
and
<string-name><surname>Viljoen</surname>
,
<given-names>M.</given-names></string-name><article-title>Lactoferrin: a general review</article-title>
.
<source>Haematologica</source>
,
<volume>80</volume>
,
<fpage>252</fpage>
&#x02013;
<lpage>267</lpage>
(
<year>1995</year>
).
<pub-id pub-id-type="pmid">7672721</pub-id></mixed-citation></ref><ref id="b13"><label>13</label><mixed-citation publication-type="journal" id="cit13">
)
<string-name><surname>Hasegawa</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Motsuchi</surname>
,
<given-names>W.</given-names></string-name>
,
<string-name><surname>Tanaka</surname>
,
<given-names>S.</given-names></string-name>
and
<string-name><surname>Dosako</surname>
,
<given-names>S.</given-names></string-name><article-title>Inhibition with lactoferrin of in vitro infection with human herpes virus</article-title>
.
<source>Jpn. J. Med. Set. Biol.</source>
,
<volume>47</volume>
,
<fpage>73</fpage>
&#x02013;
<lpage>85</lpage>
(
<year>1994</year>
).
</mixed-citation></ref><ref id="b14"><label>14</label><mixed-citation publication-type="journal" id="cit14">
)
<string-name><surname>Fujihara</surname>
,
<given-names>T.</given-names></string-name>
and
<string-name><surname>Hayashi</surname>
,
<given-names>K.</given-names></string-name><article-title>Lactoferrin inhibits herpes simplex virus type&#x02010;1 (HSV&#x02010;1) infection to mouse cornea</article-title>
.
<source>Arch. Virol.</source>
,
<volume>140</volume>
,
<fpage>1469</fpage>
&#x02013;
<lpage>1472</lpage>
(
<year>1995</year>
).
<pub-id pub-id-type="pmid">7661698</pub-id></mixed-citation></ref><ref id="b15"><label>15</label><mixed-citation publication-type="journal" id="cit15">
)
<string-name><surname>Defer</surname>
,
<given-names>M. C.</given-names></string-name>
,
<string-name><surname>Dugas</surname>
,
<given-names>B.</given-names></string-name>
,
<string-name><surname>Picard</surname>
,
<given-names>O.</given-names></string-name>
and
<string-name><surname>Damais</surname>
,
<given-names>C.</given-names></string-name><article-title>Impairment of circulating lactoferrin in HIV&#x02010;1 infection</article-title>
.
<source>Cell. Mol. BioL.</source>
,
<volume>41</volume>
,
<fpage>417</fpage>
&#x02013;
<lpage>421</lpage>
(
<year>1995</year>
).
<pub-id pub-id-type="pmid">7580836</pub-id></mixed-citation></ref><ref id="b16"><label>16</label><mixed-citation publication-type="journal" id="cit16">
)
<string-name><surname>Harmsen</surname>
,
<given-names>M. C.</given-names></string-name>
,
<string-name><surname>Swart</surname>
,
<given-names>P. J.</given-names></string-name>
,
<string-name><surname>de Bethune</surname>
,
<given-names>M. P.</given-names></string-name>
,
<string-name><surname>Pauwels</surname>
,
<given-names>R.</given-names></string-name>
,
<string-name><surname>De Clercq</surname>
,
<given-names>E.</given-names></string-name>
,
<string-name><surname>The</surname>
,
<given-names>T. H.</given-names></string-name>
and
<string-name><surname>Meijer</surname>
,
<given-names>D. K.</given-names></string-name><article-title>Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro</article-title>
.
<source>J. Infect. Dis.</source>
,
<volume>172</volume>
,
<fpage>380</fpage>
&#x02013;
<lpage>388</lpage>
(
<year>1995</year>
).
<pub-id pub-id-type="pmid">7622881</pub-id></mixed-citation></ref><ref id="b17"><label>17</label><mixed-citation publication-type="journal" id="cit17">
)
<string-name><surname>Ikeda</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Sugiyama</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Tanaka</surname>
,
<given-names>T.</given-names></string-name>
,
<string-name><surname>Tanaka</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Sekihara</surname>
,
<given-names>H.</given-names></string-name>
,
<string-name><surname>Shimotohno</surname>
,
<given-names>K.</given-names></string-name>
and
<string-name><surname>Kato</surname>
,
<given-names>N.</given-names></string-name><article-title>Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes</article-title>
.
<source>Biochem. Biophys. Res. Commun.</source>
,
<volume>245</volume>
,
<fpage>549</fpage>
&#x02013;
<lpage>553</lpage>
(
<year>1998</year>
).
<pub-id pub-id-type="pmid">9571193</pub-id></mixed-citation></ref><ref id="b18"><label>18</label><mixed-citation publication-type="journal" id="cit18">
)
<string-name><surname>Ikeda</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Nozaki</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Sugiyama</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Tanaka</surname>
,
<given-names>T.</given-names></string-name>
,
<string-name><surname>Naganuma</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Tanaka</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Sekihara</surname>
,
<given-names>H.</given-names></string-name>
,
<string-name><surname>Shimotohno</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Saito</surname>
,
<given-names>M.</given-names></string-name>
and
<string-name><surname>Kato</surname>
,
<given-names>N.</given-names></string-name><article-title>Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells</article-title>
.
<source>Virus Res.</source>
,
<volume>66</volume>
,
<fpage>51</fpage>
&#x02013;
<lpage>63</lpage>
(
<year>2000</year>
).
<pub-id pub-id-type="pmid">10653917</pub-id></mixed-citation></ref><ref id="b19"><label>19</label><mixed-citation publication-type="journal" id="cit19">
)
<string-name><surname>Yi</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Kaneko</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Yu</surname>
,
<given-names>D. Y.</given-names></string-name>
and
<string-name><surname>Murakami</surname>
,
<given-names>S.</given-names></string-name><article-title>Hepatitis C virus envelope proteins bind lactoferrin</article-title>
.
<source>J. ViroL</source>
,
<volume>71</volume>
,
<fpage>5997</fpage>
&#x02013;
<lpage>6002</lpage>
(
<year>1997</year>
).
<pub-id pub-id-type="pmid">9223490</pub-id></mixed-citation></ref><ref id="b20"><label>20</label><mixed-citation publication-type="journal" id="cit20">
)
<string-name><surname>Tanaka</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Ikeda</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Nozaki</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Kato</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Tsuda</surname>
,
<given-names>H.</given-names></string-name>
,
<string-name><surname>Saito</surname>
,
<given-names>S.</given-names></string-name>
and
<string-name><surname>Sekihara</surname>
,
<given-names>H.</given-names></string-name><article-title>Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study</article-title>
.
<source>Jpn. J. Cancer Res.</source>
,
<volume>90</volume>
,
<fpage>367</fpage>
&#x02013;
<lpage>371</lpage>
(
<year>1999</year>
).
<pub-id pub-id-type="pmid">10363572</pub-id></mixed-citation></ref><ref id="b21"><label>21</label><mixed-citation publication-type="journal" id="cit21">
)
<collab collab-type="authors">Japan Society for Cancer Therapy.</collab><article-title>Criteria for the evaluation of the clinical effects of solid cancer chemotherapy</article-title>
.
<source>J. Jpn. Soc. Cancer Ther.</source>
,
<volume>28</volume>
,
<fpage>101</fpage>
&#x02013;
<lpage>130</lpage>
(
<year>1993</year>
).
</mixed-citation></ref><ref id="b22"><label>22</label><mixed-citation publication-type="journal" id="cit22">
)
<string-name><surname>Shibuya</surname>
,
<given-names>M.</given-names></string-name><article-title>Adverse drug reaction criteria of the Japan Society for Cancer Therapy</article-title>
.
<source>Jpn. J. Cancer Chemother.</source>
,
<volume>24</volume>
,
<fpage>2036</fpage>
&#x02013;
<lpage>2041</lpage>
(
<year>1997</year>
).
</mixed-citation></ref><ref id="b23"><label>23</label><mixed-citation publication-type="journal" id="cit23">
)
<string-name><surname>Tsukiyama&#x02010;Kohara</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Kohara</surname>
,
<given-names>M.</given-names></string-name>
,
<string-name><surname>Yamaguchi</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Maki</surname>
,
<given-names>N.</given-names></string-name>
,
<string-name><surname>Toyoshima</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Miki</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Tanaka</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Hattori</surname>
,
<given-names>N.</given-names></string-name>
and
<string-name><surname>Nomoto</surname>
,
<given-names>A.</given-names></string-name><article-title>A second group of hepatitis C viruses</article-title>
.
<source>Virus Genes</source>
,
<volume>5</volume>
,
<fpage>243</fpage>
&#x02013;
<lpage>254</lpage>
(
<year>1991</year>
).
<pub-id pub-id-type="pmid">1663293</pub-id></mixed-citation></ref><ref id="b24"><label>24</label><mixed-citation publication-type="journal" id="cit24">
)
<string-name><surname>Tanaka</surname>
,
<given-names>T.</given-names></string-name>
,
<string-name><surname>Tsukiyama&#x02010;Kohara</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Yamaguchi</surname>
,
<given-names>K.</given-names></string-name>
,
<string-name><surname>Yagi</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Tanaka</surname>
,
<given-names>S.</given-names></string-name>
,
<string-name><surname>Hasegawa</surname>
,
<given-names>A.</given-names></string-name>
,
<string-name><surname>Ohta</surname>
,
<given-names>Y.</given-names></string-name>
,
<string-name><surname>Hattori</surname>
,
<given-names>N.</given-names></string-name>
and
<string-name><surname>Kohara</surname>
,
<given-names>M.</given-names></string-name><article-title>Significance of specific antibody assay for genotyping of hepatitis C virus</article-title>
.
<source>Hepatology</source>
,
<volume>19</volume>
,
<fpage>1347</fpage>
&#x02013;
<lpage>1353</lpage>
(
<year>1994</year>
).
<pub-id pub-id-type="pmid">7514558</pub-id></mixed-citation></ref><ref id="b25"><label>25</label><mixed-citation publication-type="journal" id="cit25">
)
<string-name><surname>Simmonds</surname>
,
<given-names>P.</given-names></string-name>
,
<string-name><surname>McOmish</surname>
,
<given-names>F.</given-names></string-name>
,
<string-name><surname>Yap</surname>
,
<given-names>P. L.</given-names></string-name>
,
<string-name><surname>Chan</surname>
,
<given-names>S.&#x02010;W.</given-names></string-name>
,
<string-name><surname>Lin</surname>
,
<given-names>C. K.</given-names></string-name>
,
<string-name><surname>Dusheiko</surname>
,
<given-names>G.</given-names></string-name>
,
<string-name><surname>Saeed</surname>
,
<given-names>A. A.</given-names></string-name>
and
<string-name><surname>Holmes</surname>
,
<given-names>E. C.</given-names></string-name><article-title>Sequence variability in the 5&#x02032; non&#x02010;coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity</article-title>
.
<source>J. Gen. ViroL</source>
,
<volume>74</volume>
,
<fpage>661</fpage>
&#x02013;
<lpage>668</lpage>
(
<year>1993</year>
).
<pub-id pub-id-type="pmid">8385694</pub-id></mixed-citation></ref><ref id="b26"><label>26</label><mixed-citation publication-type="journal" id="cit26">
)
<string-name><surname>Bedossa</surname>
,
<given-names>P.</given-names></string-name>
,
<string-name><surname>Poynard</surname>
,
<given-names>T.</given-names></string-name><article-title>and for The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C</article-title>
.
<source>Hepatology</source>
,
<volume>24</volume>
,
<fpage>289</fpage>
&#x02013;
<lpage>293</lpage>
(
<year>1996</year>
).
<pub-id pub-id-type="pmid">8690394</pub-id></mixed-citation></ref><ref id="b27"><label>27</label><mixed-citation publication-type="journal" id="cit27">
)
<string-name><surname>Armstrong</surname>
,
<given-names>G. L.</given-names></string-name>
,
<string-name><surname>Alter</surname>
,
<given-names>M. J.</given-names></string-name>
,
<string-name><surname>McQuillan</surname>
,
<given-names>G. M.</given-names></string-name>
and
<string-name><surname>Margolis</surname>
,
<given-names>H. S.</given-names></string-name><article-title>The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States</article-title>
.
<source>Hepatology</source>
,
<volume>31</volume>
,
<fpage>777</fpage>
&#x02013;
<lpage>782</lpage>
(
<year>2000</year>
).
<pub-id pub-id-type="pmid">10706572</pub-id></mixed-citation></ref><ref id="b28"><label>28</label><mixed-citation publication-type="journal" id="cit28">
)
<string-name><surname>Iyer</surname>
,
<given-names>S.</given-names></string-name>
and
<string-name><surname>Lonnerdal</surname>
,
<given-names>B.</given-names></string-name><article-title>Lactoferrin, lactoferrin receptors and iron metabolism</article-title>
.
<source>Eur. J. Clin. Nutr.</source>
,
<volume>47</volume>
,
<fpage>232</fpage>
&#x02013;
<lpage>241</lpage>
(
<year>1993</year>
).
<pub-id pub-id-type="pmid">8491159</pub-id></mixed-citation></ref><ref id="b29"><label>29</label><mixed-citation publication-type="journal" id="cit29">
)
<string-name><surname>Sykes</surname>
,
<given-names>J. A.</given-names></string-name>
,
<string-name><surname>Thomas</surname>
,
<given-names>M. J.</given-names></string-name>
,
<string-name><surname>Goldie</surname>
,
<given-names>D. J.</given-names></string-name>
and
<string-name><surname>Turner</surname>
,
<given-names>G. M.</given-names></string-name><article-title>Plasma lactoferrin levels in pregnancy and cystic fibrosis</article-title>
.
<source>Clin. Chim. Acta</source>
,
<volume>122</volume>
,
<fpage>385</fpage>
&#x02013;
<lpage>393</lpage>
(
<year>1982</year>
).
<pub-id pub-id-type="pmid">7105421</pub-id></mixed-citation></ref><ref id="b30"><label>30</label><mixed-citation publication-type="journal" id="cit30">
)
<string-name><surname>Baynes</surname>
,
<given-names>R.</given-names></string-name>
,
<string-name><surname>Bezwoda</surname>
,
<given-names>W.</given-names></string-name>
,
<string-name><surname>Bothwell</surname>
,
<given-names>T.</given-names></string-name>
,
<string-name><surname>Khan</surname>
,
<given-names>Q.</given-names></string-name>
and
<string-name><surname>Mansoor</surname>
,
<given-names>N.</given-names></string-name><article-title>The non&#x02010;immune inflammatory response: serial changes in plasma iron, iron&#x02010;binding capacity, lactoferrin, ferritin and C&#x02010;reactive protein</article-title>
.
<source>Scand. J. Clin. Lab. Invest.</source>
,
<volume>46</volume>
,
<fpage>695</fpage>
&#x02013;
<lpage>704</lpage>
(
<year>1986</year>
).
<pub-id pub-id-type="pmid">3787168</pub-id></mixed-citation></ref><ref id="b31"><label>31</label><mixed-citation publication-type="journal" id="cit31">
)
<string-name><surname>Hansen</surname>
,
<given-names>N. E.</given-names></string-name>
,
<string-name><surname>Malmquist</surname>
,
<given-names>J.</given-names></string-name>
and
<string-name><surname>Thorell</surname>
,
<given-names>J.</given-names></string-name><article-title>Plasma myeloperoxidase and lactoferrin measured by radioimmunoassay: relations to neutrophil kinetics</article-title>
.
<source>Acta Med. Scand.</source>
,
<volume>198</volume>
,
<fpage>437</fpage>
&#x02013;
<lpage>443</lpage>
(
<year>1975</year>
).
<pub-id pub-id-type="pmid">174393</pub-id></mixed-citation></ref><ref id="b32"><label>32</label><mixed-citation publication-type="journal" id="cit32">
)
<string-name><surname>Olofsson</surname>
,
<given-names>T.</given-names></string-name>
,
<string-name><surname>Olsson</surname>
,
<given-names>L</given-names></string-name>
,
<string-name><surname>Venge</surname>
,
<given-names>P.</given-names></string-name>
and
<string-name><surname>Elgefors</surname>
,
<given-names>B.</given-names></string-name><article-title>Serum myeloperoxidase and lactoferrin in neutropenia</article-title>
.
<source>Scand. J. Haematol.</source>
,
<volume>18</volume>
,
<fpage>73</fpage>
&#x02013;
<lpage>80</lpage>
(
<year>1977</year>
).
<pub-id pub-id-type="pmid">190672</pub-id></mixed-citation></ref></ref-list></back></article>